S. 142 · 118th Congress

Preserve Access to Affordable Generics and Biosimilars Act

Introduced on Jan 30, 2023 by Amy Klobuchar (D-MN). 10 cosponsors, 3 of them from another party. Latest action (Mar 1, 2023): Placed on Senate Legislative Calendar under General Orders. Calendar No. 20.

Stage
Reported by committee
Introduced
Jan 30, 2023
Cosponsors
10
3 from the other party
Policy area
Health
Open in the Congress explorerCongress.govAlert me

Progress

The furthest stage the measure reached. Simple and concurrent resolutions do not go to the President.

  1. Introduced
  2. Reported by committee
  3. 3Passed one chamber
  4. 4Passed both chambers
  5. 5Sent to the President
  6. 6Became law

Official title

A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products.

Subjects

  • Administrative law and regulatory procedures
  • Civil actions and liability
  • Competition and antitrust
  • Contracts and agency
  • Federal Trade Commission (FTC)
  • Intellectual property
  • Judicial review and appeals
  • Licensing and registrations
  • Manufacturing
  • Marketing and advertising
  • Prescription drugs

Summary

The Congressional Research Service has not summarized this measure yet.

Sponsor and cosponsors

Cosponsors by party as of the day they signed on. Original cosponsors signed on the day of introduction.

Amy KlobucharD-MNSponsor

Democrats · 7

Republicans · 3

Roll calls

Recorded votes on the measure. Most measures move by voice vote or unanimous consent, which record no individual positions.

No recorded roll call on this measure: it moved by voice vote or unanimous consent, or has not reached the floor.

History

Every action as published, oldest first. Roll calls link to how each member voted.

  1. Jan 30, 2023Introduced in Senate
  2. Jan 30, 2023 · SenateRead twice and referred to the Committee on the Judiciary.
  3. Feb 9, 2023 · SenateCommittee on the Judiciary. Ordered to be reported with an amendment in the nature of a substitute favorably.
  4. Mar 1, 2023Committee on the Judiciary. Reported by Senator Durbin with an amendment in the nature of a substitute. Without written report.
  5. Mar 1, 2023 · SenateCommittee on the Judiciary. Reported by Senator Durbin with an amendment in the nature of a substitute. Without written report.
  6. Mar 1, 2023 · SenatePlaced on Senate Legislative Calendar under General Orders. Calendar No. 20.

Committees

Committees and subcommittees the measure was referred to.

Agencies in its committees' jurisdiction

Analisa's mapping of committee jurisdiction to federal agencies; the bill may touch others, or none of these.

Who lobbied on it

Organizations whose lobbying reports (LD-2) name this measure. Spending is what they reported for those quarters on all issues, not on this measure alone.

  1. PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA11 reports
    $37.4M reported (all issues)
  2. ASSOCIATION FOR ACCESSIBLE MEDICINES7 reports
    $1.3M reported (all issues)
  3. PFIZER INC.7 reports
    $2.7M reported (all issues)Federal contractor: PFIZER INCAI match · 100%
  4. Chamber of Commerce of the U.S.A.6 reports
    $112.9M reported (all issues)
  5. GUIDEWELL MUTUAL HOLDING CORPORATION6 reports
    $40K reported (all issues)
  6. TEVA PHARMACEUTICALS USA, INC.6 reports
    $2.5M reported (all issues)Federal contractor: TEVA PHARMACEUTICALS USA, INC.$25.9M in contracts, FY2026AI match · 100%
  7. AARP5 reports
    $25.1M reported (all issues)
  8. ABBVIE5 reports
    $5.4M reported (all issues)Federal contractor: ABBVIE US LLC$154.6K in contracts, FY2026AI match · 100%
  9. AMERICA'S HEALTH INSURANCE PLANS, INC. (AHIP)5 reports
    $14.2M reported (all issues)
  10. AMGEN INC.5 reports
    $15.2M reported (all issues)Federal contractor: AMGEN INC.AI match · 99%
  11. Amgen USA, Inc.5 reports
    $300K reported (all issues)Federal contractor: AMGEN USA INC$126M in contracts, FY2026AI match · 100%
  12. BIOTECHNOLOGY INNOVATION ORGANIZATION5 reports
    $8.9M reported (all issues)
  13. Blue Cross and Blue Shield of Florida, Inc.5 reports
    $920K reported (all issues)
  14. Campaign for Sustainable Drug Pricing (CSRxP)5 reports
    $120K reported (all issues)
  15. Fresenius Kabi USA LLC5 reports
    Federal contractor: FRESENIUS KABI USA, LLCAI match · 100%
  16. GENENTECH INC.5 reports
    Federal contractor: GENENTECH USA, INC$939.6K in contracts, FY2026AI match · 100%
  17. GSK (fka GLAXOSMITHKLINE INC.)5 reports
    $6.3M reported (all issues)
  18. NATIONAL MULTIPLE SCLEROSIS SOCIETY5 reports
    $319.3K reported (all issues)
  19. Sanofi U.S. Services, Inc.5 reports
    $300K reported (all issues)
  20. TREA Senior Citizens League5 reports
  21. VIATRIS INC.5 reports
  22. BCBSM, Inc.4 reports
    $120K reported (all issues)
  23. BLUE CROSS BLUE SHIELD OF MICHIGAN4 reports
    $1.1M reported (all issues)
  24. Blue Cross and Blue Shield Association4 reports
    $6.2M reported (all issues)
  25. PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION4 reports
    $17.8M reported (all issues)
  26. Public Citizen4 reports
    $272.8K reported (all issues)
  27. The Campaign for Sustainable Rx Pricing4 reports
    $230K reported (all issues)
  28. BLUE CROSS AND BLUE SHIELD OF KANSAS, INC.3 reports
    $35K reported (all issues)
  29. Families USA Foundation, Inc.3 reports
    $26K reported (all issues)
  30. NOVARTIS CORPORATION3 reports
    $5.3M reported (all issues)Federal contractor: NOVARTIS PHARMACEUTICALS CORPORATION$36.2M in contracts, FY2026AI match · 100%
  31. The Cigna Group and subsidiaries (Formerly Cigna Corporation3 reports
    $5.3M reported (all issues)
  32. The ERISA Industry Committee2 reports
  33. AFL-CIO1 report
    $620K reported (all issues)Federal contractor: AFL-CIO WORKING FOR AMERICA INSTITUTE, INC. (THE)AI match · 92%
  34. Association of Accessible Medicines (formerly known as GPhA)1 report
    $60K reported (all issues)
  35. Center for Health and Democracy1 report
    $20K reported (all issues)
  36. New Venture Fund1 report

Reports filed in 2023, 2024, 2025.

Sources and method

Every figure on this page traces to these records.

  • Bill status: bills and resolutions, sponsors, actions, subjects and CRS summaries (U.S. Government Publishing Office (GovInfo), from Congress.gov (Library of Congress))GovInfo Bill Status bulk data (Congress.gov; summaries by the Congressional Research Service) · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Members of Congress, their terms, committees and identifiers (The @unitedstates project (from the Biographical Directory of the U.S. Congress, the House and the Senate))unitedstates/congress-legislators: legislators, committees and current committee membership · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: CC0 1.0 (public domain dedication)
  • House roll-call votes (Office of the Clerk, U.S. House of Representatives)Office of the Clerk, U.S. House of Representatives, roll-call vote records · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Senate roll-call votes and DW-NOMINATE scores (Voteview (UCLA Department of Political Science))Lewis, Jeffrey B., Keith Poole, Howard Rosenthal, Adam Boche, Aaron Rudkin, and Luke Sonnet (2026). Voteview: Congressional Roll-Call Votes Database. https://voteview.com/ · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: Free to use with the required citation
  • Lobbying disclosures (LD-1 registrations, LD-2 quarterly reports, LD-203 contribution reports) (Clerk of the U.S. House of Representatives)Clerk of the House, Lobbying Disclosure Act filings (organizations only; lobbyists' names are not loaded) · data current to Oct 5, 2026 · loaded Oct 5, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Positions are shown only where a roll call recorded them; voice votes and unanimous consent record none.
  • Money and votes are shown side by side; neither explains the other.